Growth Metrics

Merck (MRK) Long-Term Investments (2016 - 2026)

Merck has reported Long-Term Investments over the past 18 years, most recently at $1.1 billion for Q1 2026.

  • Quarterly Long-Term Investments rose 343.78% to $1.1 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1.1 billion through Mar 2026, up 343.78% year-over-year, with the annual reading at $956.0 million for FY2025, 106.48% up from the prior year.
  • Long-Term Investments was $1.1 billion for Q1 2026 at Merck, up from $956.0 million in the prior quarter.
  • Over five years, Long-Term Investments peaked at $1.3 billion in Q3 2023 and troughed at $238.0 million in Q2 2022.
  • The 5-year median for Long-Term Investments is $622.0 million (2023), against an average of $635.0 million.
  • Year-over-year, Long-Term Investments crashed 75.17% in 2023 and then skyrocketed 343.78% in 2026.
  • A 5-year view of Long-Term Investments shows it stood at $1.0 billion in 2022, then crashed by 75.17% to $252.0 million in 2023, then skyrocketed by 83.73% to $463.0 million in 2024, then soared by 106.48% to $956.0 million in 2025, then increased by 15.59% to $1.1 billion in 2026.
  • Per Business Quant, the three most recent readings for MRK's Long-Term Investments are $1.1 billion (Q1 2026), $956.0 million (Q4 2025), and $1.1 billion (Q3 2025).